$49.04
+4.65 (+10.48%)
Open$44.47
Previous Close$44.39
Day High$49.58
Day Low$44.47
52W High$71.50
52W Low$8.73
Volume—
Avg Volume3.29M
Market Cap2.89B
P/E Ratio—
EPS$-3.51
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
-64.3% upside
Current
$49.04
$49.04
Target
$17.51
$17.51
$11.65
$17.51 avg
$27.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 29.40M | 55.18M | 366.27M |
| Net Income | -363,275,353 | -613,755,993 | 43.81M |
| Profit Margin | -1,236.0% | -1,174.2% | 12.0% |
| EBITDA | -311,464,363 | -555,455,500 | 53.48M |
| Free Cash Flow | — | — | 19.66M |
| Rev Growth | -46.7% | -46.7% | -4.9% |
| Debt/Equity | 2.63 | 2.63 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |